All posts by medical

Cell Biology

Global Cell Therapy Market By Therapy Type, By Therapeutic Area, By End User, By Cell Type, By Regional Outlook, Industry Analysis Report and…

The Global Cell Therapy Market size is expected to reach $28. 5 billion by 2026, rising at a market growth of 26. 2% CAGR during the forecast period. Cell therapy is considered as a technology that is based on substituting dysfunctional or diseased cells with active & functional cells.

New York, April 22, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cell Therapy Market By Therapy Type, By Therapeutic Area, By End User, By Cell Type, By Regional Outlook, Industry Analysis Report and Forecast, 2020 - 2026" - https://www.reportlinker.com/p06064792/?utm_source=GNW Stem cells possess the capability to differentiate into particular cells needed for repairing damaged or defective tissues or cells, thats why they are utilized for these advanced therapies. In addition, cell therapy is used in the development of regenerative medicines, which is an interdisciplinary domain aimed at maintenance, enhancement, or restoration of cell, tissue, organ function with the help of procedures majorly associated with cell therapy.

Moreover, cells like bone marrow and blood cells, mature, immature & solid tissue cells, adult stem cells, and embryonic cells are extensively deployed in cell therapy methods. Further, transplanted cells involve embryonic stem cells (ESCs), pluripotent stem cells (iPSCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs) are bifurcated mainly two groups viz. Allogeneic cell therapy and non-Allogeneic cell therapy.

At present, there are two types of cell therapies exist. The first type is cell therapy in mainstream medicine. This category includes human embryonic stem cell therapy, mesenchymal stem cell therapy, neural stem cell therapy, Autologous cell therapy, and hematopoietic stem cell therapy. The second category is in alternative medicine and perpetuates the practice of injecting animal materials in an effort to cure diseases. This practice, as per the American Cancer Society, is not supported by any medical proof of efficiency and can have fatal results.

The outbreak of the COVID-19 pandemic has affected many biopharmaceutical units, while many cellular therapy development organizations have observed a severe impact, which is due to the complexities in logistics and manufacturing models used in this sector. Moreover, considerable and constant investment is essential to allow effective commercial translation of cell-based therapeutics, an aspect that was negatively affected in 2020, further affected the overall market growth.

Therapy Type Outlook

Based on Therapy Type, the market is segmented into Autologous and Allogeneic. The Autologous therapies segment would show gradual growth due to the massive cost associated with Autologous transplants and comparatively less relapse rates. Though, development in cell banking and companies switch towards the creation of allogenic therapy products is boosting the cell therapy market.

Therapeutic Area Outlook

Based on Therapeutic Area, the market is segmented into Malignancies, Autoimmune Disorders, Musculoskeletal Disorders, Dermatology and Others. The Malignancies market dominated the Global Cell Therapy Market by Therapeutic Area 2019, growing at a CAGR of 25.2 % during the forecast period. The Autoimmune Disorders market is experiencing a CAGR of 27.6% during (2020 - 2026). Additionally, The Musculoskeletal Disorders market would showcase a CAGR of 27.2% during (2020 - 2026).

End User Outlook

Based on End User, the market is segmented into Academic & Research Institutes and Hospitals & Clinics. In 2019, the Academic & Research Institutes segment emerged as the leading segment of the market and held the highest revenue share. The stem cells are significantly being utilized for research projects, which as a result, has contributed to a massive revenue share for the Academic & Research Institutes segment. The segment would show a similar trend during the forecast period.

Cell Type Outlook

Based on Cell Type, the market is segmented into Stem Cell, Umbilical Cord-Derived, Adipose-Derived Stem Cell, Non-Stem Cell, Bone Marrow, Blood and Others. The Stem Cell market dominated the Global Cell Therapy Market by Cell Type 2019, and would continue to be a dominant market till 2026. The Umbilical Cord-Derived market is expected to witness a CAGR of 27.7% during (2020 - 2026).

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. In 2019, North America emerged as the leading region of the global cell therapy market by obtaining the highest revenue share. The larger share of the region is due to the existence of a considerable number of centers and institutes that are undergoing R&D activities to stem cell therapy. Among the top universities in the world, 5 are based in the U.S., including Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Harvard Stem Cell Institute, Harvard University, and Yale Stem Cell Center.

The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix; Fujifilm Holdings Corporation is the major forerunner in the Cell Therapy Market. Companies such as JCR Pharmaceuticals Co., Ltd., NuVasive, Inc., Medipost Co., Ltd., Vericel Corporation, and Avantor, Inc. are some of the key innovators in the market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Fujifilm Holdings Corporation, Smith & Nephew PLC, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Medipost Co., Ltd., Stemedica Cell Technologies, Inc., NuVasive, Inc., Avantor, Inc., Vericel Corporation, and Pharmicell Co., Ltd.

Recent strategies deployed in Cell Therapy Market

Partnerships, Collaborations, and Agreements:

Mar-2021: Fujifilm collaborated with Sana Biotechnology, a biotechnology company. Under this collaboration, Sana has permitted a non-exclusive right to utilize the Fujifilm Cellular Dynamics iPSC platform for the development of commercial cell therapies. Cell therapies as a treatment modality can boost, repair, or replace human biology that includes tissues, organs, and cells.

Nov-2020: Fujifilm came into partnership with Lonza Walkersville, a leading global GMP iPSC manufacturer. In this partnership, Fujifilm Cellular Dynamics permitted Lonza a non-exclusive right to utilize their patents related to iPSC generation, which include episomal vectors and reprogramming factors, for the clinical production and differentiation of iPSC lines for cell therapies.

Apr-2020: Fujifilm Diosynth Biotechnologies (FDB) entered into a partnership with OXGENE, an industry leader in the design and development of gene therapy technologies. The partnership enables FDB to provide gene therapy products to customers with an approximate 25% lead-time reduction.

Jun-2019: JCR Pharmaceuticals extended the partnership with Mesoblast Limited, an Australian-based regenerative medicine company. This expansion aimed to utilize mesenchymal stem cells (MSCs) for curing newborns who have insufficient blood supply and oxygen to the brain, this condition is termed neonatal hypoxic-ischemic encephalopathy (HIE).

Jan-019: Medipost signed a cooperation agreement with LG Chem, the largest Korean chemical company. In this agreement, both companies conducted research to discover a stem cell drug candidate for the next two years. Medipost would be responsible for making and delivering umbilical cord blood-derived mesenchymal stem cells and LG Chem has taken charge in choosing the genes, which cause disease and stem cell generation utilizing the genetic engineering techniques

Acquisition and Mergers:

Apr-2020: JCR Pharmaceuticals acquired ArmaGen, Inc., a privately-held US biopharmaceutical company. This acquisition is a testament to the companys robust commitment to bring advanced medicines to patients with mucopolysaccharidoses and other LSDs.

Mar-2019: Smith & Nephew came into agreement to acquire Osiris Therapeutics, a fast-growing company delivering regenerative medicine products. This acquisition will improve Smith & Nephews portfolio and help instantly boost their wound management business and also offer longer-term innovations in additional channels and indications.

Product Launches and Product Expansions:

Sep-2020: Smith & Nephew introduced the HEALICOIL KNOTLESS Suture Anchor. This launch expanded its revolutionary portfolio of Advanced Healing Solutions for rotator cuff repair. This line of a product consists of the innovative REGENETEN Bioinductive Implant and novel REGENESORB Material. These are developed to support a jump start in bone healing and formation.

Mar-2020: Avantor Performance Materials introduced a new recombinant Protein A affinity chromatography resin. It is a proven downstream purification step in producing mAbs. This new Avantor recombinant protein A resin helps in coping up with these challenges.

Jul-2019: NuVasive introduced its Pulse platform. This platform integrated various technologies into multiple spine surgery procedures, which include corrections, bone fusions, and more. The modular workflow product line encompasses surgical planning, patient-specific rod bending, and 2D and 3D imaging and also alignment, navigation, neurological monitoring, and radiation reduction at the time of operation.

Jan-2019: Fujifilm Cellular Dynamics unveiled iCell Microglia. It is the immune cells of the central nervous system helps in fundamental physiological and pathological processes. The iCell Microglia is different from human iPSCs is utilized in life science research to allow the study and development of therapies for degenerative neurological diseases like Alzheimers disease.

Geographical Expansions:

Jun-2020: Avantor expanded its Bridgewater, N.J. (USA) innovation center. This expansion improved the Companys R&D support for a personalized product and bioprocess development, and custom cell & gene therapy reagent production to support the customers therapeutic products, which are developed for improvements in customized medicines.

Dec-2019: Avantor expanded its global presence by opening an innovation and customer support center in Shanghai, China. This center supports biopharma research and technology development in the region. With this expansion, Avantor has nine innovation centers across the globe. The new Avantor laboratory helps the biopharmaceutical companies to escalate the development of life-changing treatments for patients in the region.

Jan-2019: Fujifilm Cellular Dynamics, a US subsidiary of Fujifilm Corporation expanded its geographical footprints by establishing a new cGMP-compliant production facility. This expansion aimed to improve its production of iPS cells for cell therapy.

Scope of the Study

Market Segments covered in the Report:

By Therapy Type

Autologous

Allogeneic

By Therapeutic Area

Malignancies

Autoimmune Disorders

Musculoskeletal Disorders

Dermatology

Others

By End User

Academic & Research Institutes

Hospitals & Clinics

By Cell Type

Stem Cell

Umbilical Cord-Derived

Adipose-Derived Stem Cell

Non-Stem Cell

Bone Marrow

Blood

Others

By Geography

North America

o US

o Canada

o Mexico

o Rest of North America

Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Malaysia

o Rest of Asia Pacific

LAMEA

o Brazil

o Argentina

o UAE

o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

Fujifilm Holdings Corporation

Smith & Nephew PLC

Kolon TissueGene, Inc.

JCR Pharmaceuticals Co., Ltd.

Medipost Co., Ltd.

Stemedica Cell Technologies, Inc.

NuVasive, Inc.

Avantor, Inc.

Vericel Corporation

Pharmicell Co., Ltd.

Unique Offerings

See the rest here:
Global Cell Therapy Market By Therapy Type, By Therapeutic Area, By End User, By Cell Type, By Regional Outlook, Industry Analysis Report and...

Cell Biology

The Mesenchymal Stem Cells Market To Grow In Direct Proportion With Innovations KSU | The Sentinel Newspaper – KSU | The Sentinel Newspaper

The Mesenchymal Stem Cells Market report by Persistence Market Research is focusing on the fact that healthcare providers are into collection of socioeconomic information of the patients, so that tracking at any point of time is possible. This on-the-go monitoring is amongst the ongoing trends in the healthcare industry.

How about looking through the sample of Mesenchymal Stem Cells market report?https://www.persistencemarketresearch.com/samples/3309

North America dominates the global market for mesenchymal stem cell due to large number of aging population and increasing incidence of cancers. Asia is expected to show high growth rates in the next five years in the global mesenchymal stem cell market. China and India are expected to be the fastest growing mesenchymal stem cell markets in Asia-Pacific region. Some of the key driving forces for mesenchymal stem cell market in emerging countries are large pool of patients and rising government funding and support.

Want a sneak peek into the Mesenchymal Stem Cells market? Access the Table of Content of Mesenchymal Stem Cells market report!https://www.persistencemarketresearch.com/toc/3309

In recent times there is increased use of mesenchymal stem cell due to increasing aging population. Rising incidence of chronic diseases, regulatory and government support and increasing investment in stem cell biology are some of the key factors driving the growth for the global mesenchymal stem cell market. In addition, increasing use of mesenchymal stem cell as a substitute to knee replacement surgeries and other operative procedures is also fuelling the growth of the global mesenchymal stem cell market. However, lack of therapeutic advancement related to vitro properties of stem cell is the major factor restraining the growth for the global mesenchymal stem cell market.

Planning to enter the arena of Mesenchymal Stem Cells market? Prebook our Mesenchymal Stem Cells market report!https://www.persistencemarketresearch.com/checkout/3309

Numerous ethical, political and religious controversies on mesenchymal stem cell could lead a challenge for the global mesenchymal stem cell market. Some of the trends for the global mesenchymal stem cell market are increasing collaborations and partnerships and rising innovation of mesenchymal stem cell products. Some of the major companies operating in the global mesenchymal stem cell market are EMD Millipore Corporation, Cell Applications, Inc., Cyagen Biosciences, Inc., Genlantis, Inc., Advanced Cell Technology Incorporated, Stemcell Technologies Inc., Celprogen, Inc., Stemedica Cell Technologies, Aastrom Biosciences and ScienCell Research Laboratories.

Explore Extensive Coverage of Persistence Market ResearchsHealthcare Industry

About us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Contact us:

Persistence Market ResearchAddress 305 Broadway, 7th Floor, New York City, NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales sales@persistencemarketresearch.com

Read more from the original source:
The Mesenchymal Stem Cells Market To Grow In Direct Proportion With Innovations KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper

Cell Biology

Anavo Therapeutics wants Big Pharma to dust off the shelves in search of phosphatase drugs – FierceBiotech

Brand-new biotech Anavo Therapeutics knows Big Pharma has been burned by a so-called undruggable target calledphosphatases, but it's here to help now.

The company launchedtoday out of the Netherlands with 20 million ($24 million) in seed funding, ready to give this strongly neglected drug target the attention it deserves.

The seed financing was led by M Ventures and INKEF Capital as well as Taiho Ventures and Bioqube Ventures. Anavo plans to use the money to develop a proprietary drug discovery platform in oncology to finally elevate phosphatase medicines.

Phosphatases first rose to prominence in the pharmaceutical world 25 years ago when attention turned to modulating signal transduction in cells as a way to stop disease, particularly cancer. Phosphatases and kinases regulate activity of signaling pathways in cells by removing or adding a phosphate group from proteins or other molecules. If this system gets out of whack, a multitude of diseases including cancer and diabetes can proliferate.

Early research suggested that the kinase protein turned on these signaling mechanisms, while phosphatases shut things off in a cell. The focus shifted to kinase inhibitors because they were the actionable side of the transaction, and a drug class was born: Eli Lillys Olumiant for rheumatoid arthritis and Roches Rozlytrek for ROS1-positive non-small cell lung cancer and NTRK fusion-positive tumors are just two of the many examples of drugs on the market from this class already.

Phosphatases emerged as a promising target in diabetes with research suggesting the target could create small-molecule anti-diabetics, rendering insulin obsolete. The pharmaceutical industry went all in, with Novartis, AstraZeneca, Vertex and Incyte all simultaneously discovering two molecules that could be a breakthrough. But that venture failed spectacularly, according to Anavos Chief Scientific Officer Gerhard Mller, Ph.D.

That was truly the Waterloo of the phosphatase family, because billions of research funds were burned. Many, many careers were destroyed, Mller said. These people are still around in the pharma companies these days, so they still have got the hesitation.

Anavo now believes they have the science sorted out, and its time to take another hard look at phosphatases. The initial thinkingkinases turn things on and phosphatases turn them offwas incorrect.

The industry stopped 20 years ago showing interest in that target family, but of course the entire academic world continued, Mller said. Anavo has mined a rich network of scientists to stack its advisory board, including Europes Mr. Phosphatase, Mathieu Bollen, who is a professor of molecular cell biology at the University of Leuven, and Nicholas Tonks, Ph.D., a professor of cancer research at Cold Spring Harbor Laboratory.

Through Bollen and Tonks, Mller said Anavo has access to a whole treasure box of validated targets. Oncology will be the initial focus for the companys in-house drug development, but the company plans to export its expertise, according to CEO Birgit Zech, Ph.D.

Signaling is involved in all kinds of biology, so also in all kinds of disease, she said.

Rather than pursue indications outside its wheelhouseZech said the startup has no business delving into CNS disorders, for exampleAnavo would be happy to work with any pharma companies that may have phosphatase targets collecting dust somewhere, afraid to reopen the file.

What they typically do, they shelve them because they've burned their fingers in the past, and who wants to be the first person who raises their hand and says, 'Hey, here's a new phosphatase!' Zech said. Anavo could also seek partnerships such as licensing deals on any targets they develop that could be promising in indications outside of oncology.

Anavo is not the only name in the phosphatase game, although the new company plans to take a broader look at the class rather than at one or two potential molecules.

RELATED:Sanofi bags rights to Revolutions SHP2 cancer drug

Novartis has three pipeline projects in early-stage development for a SHP2 inhibitor called TNO155 in solid tumors. Mller also noted a partnership between Revolution Medicines and Sanofi on a very similar molecule they call RMC-4630. Hes not sure how the two competing projects will work togetheror notin terms of intellectual property.

The SHP2 partnership was worth $50 million upfront for Revolution with $500 million in potential milestones. Research conducted by Revolution has shown that SHP2 appears to play a role in cancer growth in up to 45% of non-small cell lung cancers, as well as colorectal and ovarian cancers as well as melanoma. RMC-4630 is currently being tested in a phase 1/2 clinical trial.

View original post here:
Anavo Therapeutics wants Big Pharma to dust off the shelves in search of phosphatase drugs - FierceBiotech

Cell Biology

Columbia researchers uncover COVID-19’s impact on brain | – University Business

The team's findings suggest inflammation may trigger neurologic damage but the virus' long-term impact on memory and mood is still unknown.

Higher education institutions have played a critical role in assisting on the front lines and behind the scenes during the COVID-19 pandemic. From vaccine development to clinic rollouts to research around the novel coronavirus, scientific and medical developments have paved the way for strategic decisions to be made on campuses, in communities and across the globe.

Some of those breakthroughs not only have helped in the moment but also will provide a working base for further discoveries and planning, around this crisis and others in the future.

Late last week, in the publication Brain, a neurology team at Columbia Universitys Vagelos College of Physicians and Surgeons revealed major findings in studies done at Irving Medical Center/New York Presbyterian Hospital. In more than three dozen patients who had contracted the virus and died, all of them had sustained significant neurologic effects from SARS-COV-2.

We observed many pathological changes in these brains, which could explain why severely ill patients experience confusion and delirium and other serious neurological effects, and why those with mild cases may experience brain fog for weeks and months, said Dr. James Goldman, professor of pathology and cell biology in psychiatry, who led the study along with professors Dr. Peter Canoll and Dr. Kiran Thakur.

They also made another important discovery.

Theres been considerable debate about whether this virus infects the brain, but we were unable to find any signs of virus inside brain cells of more than 40 COVID-19 patients, Goldman said.

Inside the report

The study was conducted on 41 patients age 38 to 97 who had been hospitalized before losing their battles to COVID-19. Some died soon after being admitted, while others passed away after months of fighting the virus. Researchers noted that about half of the patients had been intubated. In addition to the damage done to the brain, they all experience lung damage, one of the hallmarks of COVID-19.

The first thing we noticed was a lot of areas with damage from a lack of oxygen, Goldman said. They all had severe lung disease, so its not surprising that theres hypoxic damage in the brain.

Researchers noted that blood clots likely caused the hypoxic damage. In addition, Canoll said microglia, or dormant immune cells in the brain that can be triggered by diseases, were seen often in patents. It is likely the inflammation throughout the body caused those cells to be activated, so even without directly infecting brain cells, COVID-19 can cause damage to the brain, he said.

One concern is the potential long-term effects of those who have gotten the virus and the length of time their bodies may have been fighting COVID-19. Since they were found mainly in the lower brain stem area, could the movement of microglia affect memory and mood?

We know the microglia activity will lead to loss of neurons, and that loss is permanent, Goldman says. Is there enough loss of neurons (in the hippocampus) to cause memory problems? Or in other parts of the brain that help direct our attention? Its possible, but we really dont know at this point.

So, Columbia researchers will continue to study patterns. They are currently looking at those who recovered from COVID-19 but then passed away as well as patients who had pre-existing respiratory issues to determine how much of COVID-19 brain pathology is a result of the severe lung disease.

See more here:
Columbia researchers uncover COVID-19's impact on brain | - University Business

Cell Biology

Artificial intelligence model predicts which key of the immune system opens the locks of coronavirus – Newswise

Newswise The human immune defense is based on the ability of white blood cells to accurately identify disease-causing pathogens and to initiate a defense reaction against them. The immune defense is able to recall the pathogens it has encountered previously, on which, for example, the effectiveness of vaccines is based. Thus, the immune defense the most accurate patient record system that carries a history of all pathogens an individual has faced. This information however has previously been difficult to obtain from patient samples.

The learning immune system can be roughly divided into two parts, of which B cells are responsible for producing antibodies against pathogens, while T cells are responsible for destroying their targets. The measurement of antibodies by traditional laboratory methods is relatively simple, which is why antibodies already have several uses in healthcare.

"Although it is known that the role of T cells in the defense response against for example viruses and cancer is essential, identifying the targets of T cells has been difficult despite extensive research," says Satu Mustjoki, Professor of Translational Hematology.

AI helps to identify new key-lock pairs

T cells identify their targets in a key and a lock principle, where the key is the T cell receptor on the surface of the T cell and the key is the protein presented on the surface of an infected cell. An individual is estimated to carry more different T cell keys than there are stars in the Milky Way, making the mapping of T cell targets with laboratory techniques cumbersome.

Researchers at Aalto University and the University of Helsinki have therefore studied previously profiled key-lock pairs and were able to create an AI model that can predict targets for previously unmapped T cells.

"The AI model we created is flexible and is applicable to every possible pathogen - as long as we have enough experimentally produced key-lock pairs. For example, we were quickly able to apply our model to coronavirus SARS-CoV-2 when a sufficient number of such pairs were available," explains Emmi Jokinen, M.Sc. and a Ph.D. student at Aalto University.

The results of the study help us to understand how a T cell applies different parts of its key to identify its locks. The researchers studied which T cells recognize common viruses such as influenza-, HI-, and hepatitis B -virus. The researchers also used their tool to analyze the role of T-cells recognizing hepatitis B, which had lost their killing ability after the progression of hepatitis to hepatic cell cancer.

The study has been published in the scientific journalPLOS Computational Biology.

A new life for published data with novel AI models

Tools generated by AI are cost-effective research topics.

"With the help of these tools, we are able to make better use of the already published vast patient cohorts and gain additional understanding of them," points out Harri Lhdesmki, Professor of Computational Biology and Machine Learning at Aalto University.

Using the artificial intelligence tool, the researchers have figured out, among other things, how the intensity of the defense reaction relates to its target in different disease states, which would not have been possible without this study.

"For example, in addition to COVID19 infection, we have investigated the role of the defense system in the development of various autoimmune disorders and explained why some cancer patients benefit from new drugs and some do not", reveals M.D. Jani Huuhtanen, a Ph.D. student at the University of Helsinki, about the upcoming work with the new model.

###

View post:
Artificial intelligence model predicts which key of the immune system opens the locks of coronavirus - Newswise

Cell Biology

The Microfluidic Devices Market To Traverse The Exponential Growth Trajectory Between 2021 The Courier – The Courier

According to a new market report published by Persistence Market Research Global Market Study on Microfluidic Devices: Asia to Witness Highest Growth by 2019 the global microfluidic device market was valued atUSD 1,531.2 million in 2013and is expected to grow at aCAGR of 22.8%from 2013 to 2019, to reach an estimated value ofUSD 5,246.4 million in 2019.

Globally, the microfluidic device market is witnessing significant growth due to increasing R&D investment in pharmaceuticals, life science and rising point of care testing demand. New trends in healthcare, such as health care at home, supports point of care testing (POCT) as the most efficient and effective delivery of healthcare. Miniaturization also reduces the cost for screening compounds in pharmaceutical companies for cell biology problems.

Get Sample Copy of Report @https://www.persistencemarketresearch.com/samples/2995

Some of the major players in the Microfluidic Device market:

Get To Know Methodology of Report @https://www.persistencemarketresearch.com/methodology/2995

In addition, microfluidic proteomic devices are increasingly being used to quantify and identify proteins and to study interactions of different proteins with reagent in array. Different materials such as glass, silicon, polymer metal and ceramics, are used to manufacture microfluidic devices. The global microfluidic device market was valued at USD 1,531.2 million in 2013. It is likely to grow at aCAGR of 22.8%during 2013 to 2019 to reachUSD 5,246.4 millionin 2019.

In North America, rising aging population, increasing health awareness, rising chronic and lifestyle diseases, technological developments for various home use applications, and proper insurance coverage are driving the use of microfluidic devices in the market. Usage of microfluidic technology in North America is high compared to other regions of the world due to its early adoption and multiple applications in different industries.

Access Full Report @https://www.persistencemarketresearch.com/checkout/2995

In Europe, the microfluidic device market is driven by rising diagnostic requirements due to increasing lifestyle associated diseases, aging population and improving healthcare infrastructure. On the other hand, increasing healthcare costs has shifted the focus of healthcare from hospitals to home, which would increase the use of microfluidic devices in the region.

However, Asia is becoming one of the most attractive markets for medical device companies. The growth for microfluidic devices is much faster than developed countries due to widening health insurance penetration and up-gradation of health care systems. Asia is one of the producers of generic drugs, which require microfluidic devices for toxicity testing of drugs.

About us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers experience by acting as the missing link between customer relationships and business outcomes. The best possible returns are assured therein.

Contact us:

Persistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Salessales@persistencemarketresearch.comWebsite https://www.persistencemarketresearch.com

Read this article:
The Microfluidic Devices Market To Traverse The Exponential Growth Trajectory Between 2021 The Courier - The Courier

Anatomy

Greys Anatomy Fans Have Made A Big Connection Between New Derek And Meredith Episode And Heartbreaker From The Past – CinemaBlend

Spoilers ahead from Season 17, Episode 13 Good as Hell of Greys Anatomy.

On the latest episode of Greys Anatomy, fans had to say goodbye to Derek Shepherd once again, as Merediths beach fantasy came to an end as a result of her starting to recover from her battle with COVID-19. Fans, however, managed to make a connection between that episode and a heartbreaker from the past.

Read more:
Greys Anatomy Fans Have Made A Big Connection Between New Derek And Meredith Episode And Heartbreaker From The Past - CinemaBlend

Anatomy

‘Grey’s Anatomy’: The ‘Fake’ American Accent That Bothers Fans the Most – Showbiz Cheat Sheet

There are a lot of interns and doctors who have made their way through the doors of Grey Sloan Memorial Hospital in Greys Anatomy over the last decade or more, meaning there are several different personalities, accents, and beliefs introduced to fans. However, not all of them have become highly favored by viewers, especially one accent in particular.

Since she arrived at Greys in 2012, fans have always loved the concept of Jos character and her resilience, but they are not impressed with her fake American accent.

RELATED: Greys Anatomy: Camilla Luddington Thanks Fans For the Jo Love on Her Characters Anniversary

The up-and-coming star has been in the limelight since she entered Greys in 2012, but she has also had some memorable performances as Lara Croft in Tomb Raider and Rise of the Tomb Raider, and as Zatanna in the Justice League Dark.

Although Luddington is mostly known for her fictional American character Jo, she is actually British (accent and all!) in real life. Dual citizenship aside, The Famous People reports that she was born in Ascot, Berkshire, England, and didnt make her way to American until she moved to Austin, Texas as a teenager.

RELATED: Greys Anatomy Showrunner Says It Would Have Been Dull to Keep Jo and Alex Together

On Greys Anatomy, Luddingtons character is an attending general surgeon at Grey Sloan Memorial Hospital. Jo has a heartbreaking past of abandonment and abuse that many couldnt help but compare to the tragic upbringing of Alex making them a good fit.

Fans loved her for her character development and relationship with Alex but got a bombshell of a shock when it came out that she was already married, and Jo Wilson wasnt even her real name its Brook Stadler.

The strong female character moves past this problem only to face many more before and after the highly-loved romance. Ranging from many other troubling relationships, struggles with her career, drama with co-workers, and much more.

RELATED: Greys Anatomy: Why Camilla Luddington Doesnt Think Jo Wilson Needs Alex Karev to Come Back

In a Reddit forum created to complain about Luddingtons character, one Reddit user admitted, Her American accent is kinda annoying, sometimes her British accent is breaking through and prompted others to chime in.

This brought about a conversation on why she wasnt just introduced as a British character, to begin with. Some fans think that wouldve been better than making her mask her accent altogether.

I think it would have been better to let Camilla play a British character in the first place, another Reddit user complained. Then she wouldnt have to fake an American accent.

Another fan gave one theory, saying that they did actually get her to audition with both accents and went with American. I am guessing it would be harder for Jo to be a female Alex if she was British, and the ex-street kid thing would be even more unbelievable, for her to be able to emigrate to US and attend a top school, etc

Jo has always been a controversial topic since her debut on the show, but over the years, many fans have actually grown to love the person her character has evolved into being. However, unbelieving accent aside, fans think Camilla Luddingtons Jo is steadily being written off the show. This comes after the shocking news of Alex Karev running back to ex-wife Izzie and leaving Jo behind to pick up the pieces. Only time will tell as this season nears its ending, and something crazy is sure to happen.

Read more:
'Grey's Anatomy': The 'Fake' American Accent That Bothers Fans the Most - Showbiz Cheat Sheet

Anatomy

Sarah Drew and Jesse Williams Reunite as April and Jackson on Greys Anatomy: Episode Photos – Us Weekly

Japril fans, this ones for you! Sarah Drews return as Dr. April Kepner on Greys Anatomy is coming up and ABC has finally released teaser photos from the May episode.

The network dropped a series of stills from the upcoming episode on Tuesday, April 20, showing Aprils reunion with Jackson Avery (Jesse Williams). While fans wont see the former couples interaction play out on the drama until Thursday, May 6, the photos tease a slew of emotions from both doctors when they first see each other.

The snaps, which show April and Jackson sharing a meal and having a glass of wine together, come two months after Williams, 39, revealed he was rooting for his character to be with April again.

They are incredible together, the Little Fires Everywhere actor told Entertainment Tonight in February. I am a fan [of Sarahs] and she is absolutely one of the most special people Ive worked with. We developed those story lines together with our incredible writers, so itll always hold a very real place in my heart and memories. We stay in contact. She is the sweetest.

The following month, the pairs castmate Camilla Luddington teased Drews comeback after a fan asked if she had seen any alums on set. I did happen to run into a gorgeous red head I have missed SO. DAMN. MUCH!! she tweeted in March.

Us Weekly confirmed on March 12 that Drews character would return during season 17 of the series.

Drew, 40, exited the medical drama at the end of season 14 in 2018 after nine seasons. During her time on the show, her character, April, fell in love with fellow doctor Jackson and they later welcomed a daughter together before getting divorced.

To many fans disappointment, April married Matthew (Justin Bruening) during a May 2018 and subsequently quit her job at Grey Sloan Memorial Hospital. Next month, however, viewers will learn what April has been doing since her departure and where she stands with Jackson.

The New York native documented her reunion with her costars last month, highlighting her excitement upon being back with Williams. Nbd. Not excited at all. , the Cruel Summer actress wrote via Instagram in March alongside a photo of the duo masked-up on set.

Williams shared his own video of the duos time together, captioning it with a present emoji.

Its 4am. Do you know where your #japril is? #onset @ijessewilliams, Drew wrote alongside a video snuggling up to Williams during an early morning shoot two days later.

Earlier this month, the Moms Night Out actress revealed that her episode will air in May, sparking fans to freak out. SO EXCITED, the Greys Anatomy official Instagram page commented on her announcement.

Following the Thursday, April 22, episode of Greys Anatomy, fans got their first video footage of the pairs reunion in the teaser.

This seems impulsive and out of nowhere, but its not, Jackson tells himself as he rings Aprils doorbell. Its just Ive thought it through, Ive just thought it through very

April subsequently opens the door with their daughter Harriet in hand.

Drews highly-anticipated comeback follows the return of Derek Shepherd (Patrick Dempsey) and George OMalley (T.R. Knight), who were both killed off earlier in the series, as part of Meredith Greys (Ellen Pompeo) dream sequence. Merediths sister Lexie Grey (Chyler Leigh) and Mark Sloan (Eric Dane) also made cameos this season.

Scroll down to see April and Jacksons reunion ahead of the May 6 episode of Greys Anatomy:

More here:
Sarah Drew and Jesse Williams Reunite as April and Jackson on Greys Anatomy: Episode Photos - Us Weekly

Anatomy

‘Grey’s Anatomy’ Season 17: Meredith and Derek Predicted That Wedding Scene Back in Season 5 – Showbiz Cheat Sheet

Greys Anatomy Season 17 proved April 22 was a beautiful day to cry over Derek Shepherd (Patrick Dempsey) and Meredith Grey (Ellen Pompeo). In the all-new episode, MerDer reunited one last time on Limbo Beach. Then Meredith and Dereks dream wedding finally came to life, and many fans noticed that the couple predicted the moment back in Greys Anatomy Season 5. Heres a breakdown of each emotional moment.

RELATED: Greys Anatomy: Why Patrick Dempsey Is Happy Fans Still Call Him McDreamy

Long before Dereks death and his dream beach reunion with Meredith in Greys Anatomy Season 17, the couple got married on a Post-It note. In the fifth season finale, Meredith and Derek planned to tie the knot at city hall. However, they were extremely busy between Izzie Stevens (Katherine Heigl) and George OMalley (T.R. Knight), who happened to be John Doe at the time.

Nevertheless, Meredith and Derek decided to get married and start their forever together. But they only had blue Post-It notes on hand. So they wrote out their vows to each other and called it their wedding.

[We promise] to love each other, even when we hate each other, Meredith and Derek said. Nobody walks out, no matter what happens. No running. Well take care of each other, even when were old and smelly and senile. This is forever.

Meanwhile, Meredith and Derek were legally married in Greys Anatomy Season 7 Episode 20.

RELATED: Greys Anatomy: Derek and Merediths Goodbye Will Break You After Their Last Scene Together in Season 17

In Greys Anatomy Season 17, fans finally watched Meredith and Derek in full-on wedding attire. But the moment happened on Merediths dream beach six years after her husbands death. In episode 13, Meredith told Derek their daughter, Ellis, wasnt satisfied with their Post-It wedding.

Ellis draws this picture of us, Meredith said. Im in a wedding dress, and youre in a suit. I showed her the Post-It note, but she just hates it. She feels robbed!

Suddenly, Ellis fantasy came true. Meredith and Derek stood on the beach in a wedding dress and suit. The general surgeon also admitted she hated weddings. But she would give this moment to Ellis if she could.

In the end, Meredith and Derek made a new vow. The former neurosurgeon wanted his wife to torture herself less. Then both parties suggested it was time for Meredith to wake up from the dream.

I dont want to leave the kids, Meredith said, and Derek echoed her. Finally, the couple shared a kiss on the beach.

RELATED: Greys Anatomy: Jesse Williams and Sarah Drew React to Jackson and Aprils Season 17 Reunion

Following Meredith and Dereks dream beach wedding in Greys Anatomy Season 17, many fans pointed out that the couple discussed their seaside ceremony plans back in season 5. As you may remember, MerDers Post-It wedding wasnt exactly their first choice or even close to second.

In Greys Anatomy Season 5 Episode 22, the couple gave their big wedding to Izzie and Alex Karev (Justin Chambers) because of Izzies brain tumor. Then at the start of the next episode, Derek told Meredith their new wedding plans after discovering how to help Izzie.

When Izzies in the clear, were gonna go to the Bahamas and have our wedding on the beach, Derek said. The One & Only Beach Club. You can actually have drinks during the ceremony.

While Meredith and Dereks Post-It wedding will be remembered forever, the couple finally got their dream beach ceremony in Greys Anatomy Season 17. Now, viewers must wait for the next all-new episode on Thursday, May 6. Stay tuned.

Visit link:
'Grey's Anatomy' Season 17: Meredith and Derek Predicted That Wedding Scene Back in Season 5 - Showbiz Cheat Sheet